New perspectives in ovarian cancer treatment

被引:52
作者
Schmid, Bernd C. [1 ]
Oehler, Martin K. [1 ,2 ]
机构
[1] Royal Adelaide Hosp, Dept Gynaecol Oncol, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Robinson Inst, Res Ctr Reprod Hlth, Discipline Obstet & Gynaecol, Adelaide, SA 5005, Australia
关键词
Ovarian cancer; Targeted therapy; Anti-angiogenic therapy; PARP inhibitors; Immunotherapy; Intraperitoneal chemotherapy; PHASE-II TRIAL; RECURRENT EPITHELIAL OVARIAN; PLATINUM-RESISTANT; PRIMARY PERITONEAL; FALLOPIAN-TUBE; CLINICAL ACTIVITY; BREAST-CANCER; GROWTH-FACTOR; DOUBLE-BLIND; CHEMOTHERAPY;
D O I
10.1016/j.maturitas.2013.11.009
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Ovarian cancer (OC) is increasingly understood as a heterogeneous disease comprising distinct subtypes of different origin that vary significantly with regard to molecular biology and clinical behaviour. Despite some limited progress in its treatment over the last decade, currently there are few therapeutic options and overall survival remains poor. Increasing knowledge about the molecular biology of ovarian cancer has led to the development of targeted therapies which promise to be more effective and to provide the basis for personalized treatment. The most successful strategies so far are employing anti-angiogenics (VEGF antibodies, tyrosine kinase inhibitors and angiopoietin antagonists) and polyadenosine diphosphate-ribose polymerase (PARP) inhibitors. Other approaches target aberrant CC signalling such as the PI3K/Akt/mTOR network, the epidermal growth factor receptor, the WEE1 tyrosine kinase and the folate receptor alpha. Immunotherapy is another promising new approach against ovarian cancer. In this area, immunotherapeutic modulation by administering autologous immune cells, such as dendritic cells (DCs), to stimulate antitumour host responses is of special interest. Finally, there is now growing evidence from clinical studies showing a survival advantage for intraperitoneal (IP) chemotherapy when compared to conventional intravenous treatment in the adjuvant setting. New strategies such as pressurized IF aerosol chemotherapy might further improve the efficacy of this approach. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:128 / 136
页数:9
相关论文
共 89 条
[1]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[2]   Trebananib Boosts PFS in Ovarian Cancer [J].
不详 .
CANCER DISCOVERY, 2013, 3 (08) :831-831
[3]  
[Anonymous], J CLIN ONCOL S
[4]  
[Anonymous], ESMO ANN M
[5]   A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer [J].
Argenta, Peter A. ;
Thomas, Sajeena G. ;
Judson, Patricia L. ;
Downs, Levi S., Jr. ;
Geller, Melissa A. ;
Carson, Linda F. ;
Jonson, Amy L. ;
Ghebre, Rahel .
GYNECOLOGIC ONCOLOGY, 2009, 113 (02) :205-209
[6]   A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].
Ashworth, Alan .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790
[7]  
Berek JS, 2012, ASCO M
[8]   Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].
Bookman, MA ;
Darcy, KM ;
Clarke-Pearson, D ;
Boothby, RA ;
Horowitz, IR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290
[9]  
Bowman A, 2002, CLIN CANCER RES, V8, P2233
[10]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917